MedTrace Logo

Deferred Embryo Transfer in an In Vitro Program With Single Embryo Transfer Policy

NCT05721495 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2023-02-10

No results posted yet for this study

Summary

Single embryo transfer decreases the multiple pregnancy rate and its complications. However, studies are needed to help increase the effectiveness of this technique to increase its use, which undoubtedly improves the safety of our patients.

Objectives:

To assess the results of IVF / ICSI cycles with single embryo transfer, in terms of both pregnancy and live birth rates, comparing a group of patients in which an elective delayed cryotransfer of an embryo without fresh transfer is performed (experimental group ), with patients in whom a fresh embryo is transferred electively.

Methodology:

A prospective randomized clinical trial with two arms in parallel, not blinded, including 138 couples using an IVF / ICSI cycle at the Reproduction Unit of the Hospital Universitario Virgen de las Nieves de Granada. The inclusion criteria classify them as having a good reproductive prognosis, and the patients will follow an ovulation treatment protocol with GnRH agonists or antagonists. Couples will undergo an IVF / ICSI cycle, randomly assigned to:

* Group I (experimental): fresh transfer is not performed, the best quality embryo is cryopreserved. Elective transfer in a later cycle of the cryopreserved embryo.
* Group II (control): fresh transfer of the best quality embryo.

Conditions

  • Single Embryo Transfer
  • Embryo Implantation, Delayed
  • Pregnancy Rate

Interventions

OTHER

freeze all strategy embryo transfer

criopreservation of all viable embryos in order to transfere the best one in a posterior cycle

OTHER

fresh embryo transfer strategy

transfer of the best embryo two or three days after the fecundation technique

Sponsors & Collaborators

  • Junta de Andalucia

    collaborator OTHER_GOV

  • University Hospital Virgen de las Nieves

    lead OTHER

Principal Investigators

  • Ana Clavero-Gilabert, PhD · HU Virgen de las Nieves

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2022-02-28
Completion
2022-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05721495 on ClinicalTrials.gov